Mirati Shares Fall On New Data For Lung Cancer Drug Combo | Enterpreneurship
Want create site? Find Free WordPress Themes and plugins.
Shares of San Diego-based Mirati Therapeutics fell 15 percent Monday as data from an ongoing mid-stage study of one of its experimental cancer drugs disappointed investors.
Mirati (NASDAQ: MRTX) is one of several biotech companies trying to get in on the mix-and-match cancer immunotherapy game. Drugmakers have been combining immunotherapies with other medicines hoping to help more patients respond, and that has led to a slew of deals and alliances to test various regimens in clinical trials. Results so far have been mixed.
Mirati, for instance, has been testing sitravatinib (MGCD516) in combination with nivolumab (Opdivo), an immunotherapy from… Read more »
Reprints | Share: 
UNDERWRITERS AND PARTNERS
Did you find apk for android? You can find new Free Android Games and apps.